Bavarian Nordic A/S (CPH:BAVA)(OTC: BVNRY), a biotechnology company focused on the development of innovative therapies against infectious diseases and cancer, announced on Thursday the submission by its partner, Janssen Pharmaceutical Companies of Johnson & Johnson, of Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA) seeking licensure for an investigational Ebola vaccine regimen for the prevention of Ebola Virus Disease (EVD) caused by Zaire Ebola virus.
Reportedly, two MAAs have been submitted in parallel supporting each vaccine in the two-dose regimen (Ad26.ZEBOV, MVA-BN Filo). The EMA's Committee for Medicinal Products for Human Use (CHMP) granted an Accelerated Assessment in September 2019, which will shorten the review time for these applications.
This vaccine regimen includes Ad26.ZEBOV as the first dose, which is based on Janssen's AdVac technology, and MVA-BN Filo as the second dose, which is based on Bavarian Nordic's MVA-BN technology and is administered approximately eight weeks later.
These MAAs are supported by data from phase 1, 2 and 3 clinical studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children, preclinical studies, and immunobridging analyses. To date, more than 6,500 volunteers across the US, Europe and Africa have participated in over 10 clinical studies of the vaccine.
Also, Janssen has ongoing discussions with the US Food and Drug Administration (FDA) to define the required data set for filing of the Ebola vaccine regimen under the FDA's Animal Rule licensure pathway and is also working in collaboration with the World Health Organisation (WHO) to enable registration of the Ebola vaccine regimen in African countries.
On 31 October 2019, Janssen announced that it will provide up to 500,000 regimens of its investigational vaccine to the Democratic Republic of Congo (DRC) for use in a new clinical trial organised by the DRC government and global health stakeholders in an effort to contain the country's Ebola outbreak.
Upon EMA approval of the MVA-BN Filo vaccine, Bavarian Nordic would be eligible to receive a milestone payment of USD10m under the licence agreement with Janssen.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients